Revolution Medicines surges on unprecedented survival data in Phase 3 pancreatic cancer trial
Revolution Medicines (NASDAQ:RVMD) shares jumped 36% in pre-market trading Monday after the company reported positive topline results from its global Phase 3 RASolute 302 study.










